Chronic Hepatitis C Virus Infections in Leukemia Survivors: Prevalence, Viral Load, and Severity of Liver Disease

By Ian M. Paul, Jeffrey Sanders, Francesca Ruggiero, Thomas Andrews, David Ungar, and M. Elaine Eyster

The natural history of chronic hepatitis C (HCV) infections in long-term leukemia survivors has not been well characterized. We studied the prevalence of HCV infections, measured HCV RNA levels, and evaluated the severity of liver disease in patients with leukemia who achieved long-term remissions after intensive chemotherapy or bone marrow transplantation (BMT). HCV antibody tests were performed by the enzyme-linked immunoblot assay (ELISA) and positive tests confirmed by the recombinant immunoblot assay (RIBA). HCV RNA levels were measured by the branched DNA (bDNA) assay. Seventy-five leukemia survivors with 25 or more blood donor exposures were identified. Nine (12%) were anti-HCV positive. All were infected before 1992 when second generation HCV screening tests were implemented.

In all, 52 of the anti-HCV positive leukemia survivors were anti-HCV positive at the time of BMT. Of the 16 others, 14 had been infected before 1992, 1 was infected after 1992 but before BMT, and 1 was infected after BMT. Eighty-three percent of the anti-HCV positive leukemia survivors who achieved a complete remission after intensive chemotherapy or BMT had been infected before 1992.

HCV RNA levels were measured by the Quantiplex 1.0 bDNA assay in 40 of the anti-HCV positive leukemia survivors. Anti-HCV positive leukemia survivors have significantly higher viral loads than those who are coinfected with human immunodeficiency virus (HIV). Previous studies have shown that HCV RNA levels increase as the immune deficiency progresses. Coinfection with HIV has also been shown to be associated with an increased risk of cirrhosis and liver failure.

The objectives of this study were (1) to determine the prevalence of HCV infection and severity of liver disease in anti-HCV positive adults and children with leukemia who achieved a complete remission after intensive chemotherapy or allogeneic BMT and (2) to determine whether HCV load differed in the study group compared with a control group of immunocompetent anti-HCV positive hemophiliacs.

MATERIALS AND METHODS

Subjects. The records of all patients with leukemia who were seen between 1973 and 1995 at the adult and pediatric hematology clinics at the Hershey Medical Center and in the practices of five physician groups in the Central Pennsylvania area were reviewed to identify those who had achieved a complete remission after intensive chemotherapy or BMT. Patients less than age 21 at the time of diagnosis were classified as children. Seventy-five patients in active follow-up who met study criteria were identified. They consisted of 46 adults and 29 children with acute leukemia or chronic myelogenous leukemia (CML) who had received 25 or more donor exposures to blood products. Four patients were known to be anti-HCV positive at the initiation of the study. After obtaining informed consent, medical records were reviewed and histories were obtained to exclude other causes for hepatitis. Blood was then drawn for HCV antibody testing and HCV RNA levels.

The control group consisted of 20 anti-HCV positive, anti-HIV negative, otherwise healthy, randomly selected hemophilia patients with known transfusion dates followed regularly at the hemophilia clinic at the Hershey Medical Center and enrolled in a prospective cohort study on HIV initiated in 1982. For these individuals, sera routinely collected during the previous year and stored frozen at −70°C was tested for HCV RNA.

Detection of HCV infection and quantitation of HCV RNA levels. Sera were tested with the enzyme-linked immunosorbent assay (ELISA) (Ortho Diagnostic System, Raritan, NJ) and positive tests were confirmed by a second generation recombinant immunoblot assay test (RIBA-2) (Chiron Corp, Emeryville, CA). Samples were considered positive if they reacted with two or more of the four test antigens. Serum HCV RNA levels were measured by the Quantiplex 1.0 bDNA assay (Chiron Corp) on all who were anti-HCV positive except for one patient from a community practice who had the quantitative polymerase chain reaction (PCR)-based Monitor test (Roche Molecular Systems, Nutley, NJ) performed by an outside laboratory. All who were below the cut off...
(<3.5 × 10^3 eq/mL) were subsequently tested by the 2.0 assay (cut off 0.2 × 10^6 eq/mL). Those who were negative by the bDNA assay as well as a subset of leukemia patients who were anti-HCV negative were tested for HCV RNA by the more sensitive, qualitative PCR assay as previously described. To obtain a mean value of HCV RNA load for the control group, PCR positive samples below the detectable limits of the bDNA assay of 0.2 × 10^6 eq/mL were assigned a value of 0.1 × 10^6 eq/mL (half the detectable limit) and PCR negative samples were assigned a value of .001 × 10^6 eq/mL (approaching the lowest level of 1,000 viral copies/mL detectable by PCR).

**Estimation of duration of infection.** For the patients with acute leukemia, the date of infection was estimated to be the initial exposure to blood products during the induction phase of chemotherapy. For patients with CML undergoing allogeneic BMT, the date of transplant was assumed to be the date of infection. For hemophilia patients, the midpoint between the maximum duration of infection (the number of years since first transfusion) and the minimum duration of infection (the number of years since first exposure to unsterilized clotting factor concentrates) was used. The minimum duration of infection for the hemophilia patients can be accurately estimated because studies have shown a near 100% incidence of infection with HCV after the first infusion of unsterilized clotting factor concentrates obtained from large donor pools. For the five subjects who had received only single donor blood products or only virally attenuated concentrates, the minimum duration of infection was estimated from known duration of transaminase elevations.

**Evaluation of liver histology.** Percutaneous liver biopsy specimens were evaluated blindly by a single pathologist and scored using the Knodell total histology activity index (HAI), which is a grading system for chronic hepatitis frequently used in clinical studies.

**Statistical analysis.** Exact P values were calculated using the Pearson’s χ² test to determine the statistical significance of the difference between the prevalence of detectable HCV RNA in the study and control groups and prevalence of anti-HCV in (1) acute lymphoblastic leukemia (ALL) versus acute myelogenous leukemia (AML); (2) the two donor exposure groups; and (3) the three time periods examined. To compare the HCV RNA values between the two groups, a Wilcoxon rank sum test was used to determine the exact P value, and a two sample t-test was used to compare the duration of infection data.

**RESULTS**

**Prevalence of HCV infection in the study cohort.** Nine (12.0%) of the 75 patients with leukemia who met the study criteria were found to be anti-HCV positive by ELISA and confirmed with the RIBA-2 assay (Table 1). Six were males and three were females. Eight were treated for AML. One of the eight received an allogeneic BMT. The ninth received an allogeneic BMT for CML. None of the 27 subjects with ALL including four allogeneic BMT recipients were anti-HCV positive compared with 8 of 37 (21.6%) with AML (P = .046). Of the 17 allogeneic BMT recipients, 2 (11.8%) were anti-HCV positive. Three (10.3%) of 29 children were anti-HCV positive. All 3 were among the 8 children treated for AML. None of 3 children treated with BMT were anti-HCV positive. The rate of HCV infection was 3 of 44 (6.8%) among those with 25 to 99 donor exposures compared with 6 of 31 (19.4%) among those with 100 or more donor exposures (P = .15). Six (19.4%) of 31 patients who were anti-HCV positive were transfused before June 1990, when first-generation anti-HCV testing was implemented. Three (20.0%) of 15 patients transfused while first generation tests were in use tested positive. None of the 29 subjects studied after second generation testing was implemented in 1992 were positive for anti-HCV (P = .04).

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>No. of Patients</th>
<th>Anti-HCV Positive</th>
<th>Anti-HCV Negative</th>
<th>Total (% positive)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALL</td>
<td>0</td>
<td>27</td>
<td>27</td>
<td>0</td>
</tr>
<tr>
<td>Age &lt;21 yr</td>
<td>0</td>
<td>21</td>
<td>21</td>
<td>0</td>
</tr>
<tr>
<td>BMT</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Age ≥21 yr</td>
<td>0</td>
<td>6</td>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td>BMT</td>
<td>0</td>
<td>3</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>AML</td>
<td>0</td>
<td>3</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Age &lt;21 yr</td>
<td>0</td>
<td>5</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>BMT</td>
<td>0</td>
<td>2</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Age ≥21 yr</td>
<td>0</td>
<td>32</td>
<td>32</td>
<td>0</td>
</tr>
<tr>
<td>BMT</td>
<td>0</td>
<td>7</td>
<td>7</td>
<td>0</td>
</tr>
<tr>
<td>CML*</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>33</td>
</tr>
</tbody>
</table>

**Total patients** | 9               | 66                | 75                | (12)               |

<table>
<thead>
<tr>
<th>Donor exposures</th>
<th>No. of Patients</th>
<th>Anti-HCV Positive</th>
<th>Anti-HCV Negative</th>
<th>Total (% positive)</th>
</tr>
</thead>
<tbody>
<tr>
<td>25-99</td>
<td>3</td>
<td>41</td>
<td>44</td>
<td>(7)</td>
</tr>
<tr>
<td>100 or more</td>
<td>6</td>
<td>25</td>
<td>31</td>
<td>(19)</td>
</tr>
<tr>
<td>Time of first transfusion</td>
<td>No. of Patients</td>
<td>Anti-HCV Positive</td>
<td>Anti-HCV Negative</td>
<td>Total (% positive)</td>
</tr>
<tr>
<td>Before J une 1990</td>
<td>6</td>
<td>25</td>
<td>31</td>
<td>(19)</td>
</tr>
<tr>
<td>J une 1990-December 1991</td>
<td>3</td>
<td>12</td>
<td>15</td>
<td>(20)</td>
</tr>
<tr>
<td>1992-present</td>
<td>0</td>
<td>29</td>
<td>29</td>
<td>(0)</td>
</tr>
</tbody>
</table>

*All age 21 or more and all received allogeneic BMT.

**Characteristics of the anti-HCV positive leukemia patients.** The nine anti-HCV positive patients had a mean age of 36.2 ± 15.4 (standard deviation [SD]) years with a range of 7 to 50 years at the time of evaluation and were estimated to be infected for a mean of 9.0 ± 4.4 years with a range of 4 to 16 years (Table 2). Seven (78%) had mild to moderately elevated serum alanine transaminase.

**Liver histology in anti-HCV positive leukemia patients.** Six (67%) of nine anti-HCV positive patients had liver biopsies performed after a mean of 9 years (range, 4 to 16 years) from the estimated date of infection (Table 2). The mean Knodell score was 8.7 (range, 5 to 13). Two (33%) of the six showed moderate to marked piecemeal necrosis. One (17%) showed moderate intralobular inflammation/necrosis. All six showed at least a moderate degree of portal inflammation and half showed moderate degree of portal inflammation and half showed moderate degree of portal inflammation and half showed moderate degree of portal inflammation and half showed moderate degree of portal inflammation and half showed moderate degree of portal inflammation and half showed moderate degree of portal inflammation and half showed moderate degree of portal inflammation and half showed moderate degree of portal inflammation and half showed moderate degree of portal inflammation and half showed moderate degree of portal inflammation and half showed moderate degree of portal inflammation and half showed moderate degree of portal inflammation and half showed moderate degree of portal inflammation and half showed moderate degree of portal inflammation and half showed
evidence of bridging fibrosis. One showed severe fibrosis consistent with cirrhosis. The patient with the highest Knodell score had the highest viral load, and two of the three patients with scores of 10 or greater had viral loads greater than $10^6$ eq/mL.

**Characteristics of the anti-HCV positive patients with hemophilia.** The 20 hemophiliacs chosen at random for the control group had a mean age of 30.7 ± 18.2 years with a range of 10 to 65 years. These individuals had an estimated mean duration of infection of 17.8 ± 6.5 years with a range of 9 to 28 years. Twelve (60%) had mild to moderately elevated transaminases. All had normal bilirubin and albumin levels, and none showed clinical evidence of liver disease at the time of study. One subsequently developed signs of portal hypertension with splenomegaly and mild thrombocytopenia. Twelve (60%) had elevated serum alanine transferases, none showed clinical evidence of liver disease at the time of study. One was known to have chronic HCV infection for more than 20 years, with no clinical or biochemical evidence of liver disease. Two had mild to moderate transaminase elevation at the time of study, and none showed clinical evidence of liver disease.

**Comparison of HCV RNA levels in leukemia patients and hemophilia controls.** Mean HCV RNA levels in the leukemia patients were $10^6$ eq/mL, compared with $3.2 \times 10^6$ eq/mL in the hemophilia controls ($P = .056$). HCV RNA levels were above the detectable limit of $0.2 \times 10^6$ eq/mL in all nine leukemia patients compared with only 12 of 20 hemophilia controls ($P = .067$). Furthermore, values above $20.0 \times 10^6$ eq/mL were found only in the leukemia group. The estimated duration of infection was 9.0 ± 4.4 years in the leukemia group compared with 17.8 ± 6.5 years in the control group ($P = .001$). The mean age of the two groups was comparable, although the range was broader for the controls.

**DISCUSSION**

The 12% prevalence of anti-HCV seropositivity in this group of leukemia patients who achieved a complete remission after chemotherapy or BMT is in the range reported by others. The 10.3% prevalence in children and the 11.8% seropositivity rate among allogeneic BMT recipients are also within the reported ranges, which vary widely depending on the year of exposure, the number of transfusions, and geographic considerations. No further cases of anti-HCV positivity were found after second generation testing of blood donors was used in 1992. These results are similar to previous reports and are consistent with the current estimated risk of HCV infection via transfusion of 1 in 103,000 donor exposures reported by Schreiber et al using the second generation ELISA test to screen for anti-HCV.

Although 78% of our anti-HCV positive patients had elevated serum alanine transferases, none showed clinical evidence of hepatic decompensation after a mean of 9 years from the estimated date of infection. This relatively benign course in HCV positive leukemia survivors through the first decade of chronic infection is in agreement with previous reports. Two large studies by Kiyosawa et al and Tong et al have focused on the pathologic evolution of hepatitis C-related liver disease in transfusion recipients. These studies showed progression to chronic hepatitis to cirrhosis to hepatocellular carcinoma after a mean duration of HCV infection of approximately 1, 2, and 3 decades, respectively. In another study, Yano et al showed that those with severe inflammation or fibrosis usually developed cirrhosis within 10 years. Our data show that all six patients who were biopsied showed moderate to severe hepatic inflammation and half had either severe fibrosis or cirrhosis after a mean of less than one decade of infection. Although these
results must be interpreted with caution because of the small sample size, this finding suggests that leukemia survivors with chronic HCV may have more rapidly progressive liver disease than has been previously recognized.

The pathogenesis of liver cell damage by HCV is not well understood. However, evidence is emerging that both host cytopathic T-lymphocyte responses and direct viral injury play a role. Reports that patients with high HCV RNA viral loads have more severe liver disease and that HCV runs a more aggressive course in patients with immune deficiency lend support to the direct hepatic cellular toxic effect of the virus. However, HCV-specific CD8 and CD4 lymphocyte responses have been shown in the liver of individuals with HCV infection. Furthermore, in one study, those with intrahepatic HCV-specific CD8 activity had lower levels of viremia and more active liver disease than those without CD8 activity. This suggests that the level of CD8 response might be responsible for much of the ongoing hepatocellular injury, and that the balance between viral and host factors may be an important determinant of hepatocellular injury. In patients with leukemia, the disease process, chemotherapy, and BMT all affect cell-mediated and humoral immunity, which may contribute to the pathogenesis of liver disease. The immunocompromised status at the time of infection may also play a role, while chemotherapy-induced hepatotoxicity may accelerate the inflammatory and fibrotic hepatic changes.

Previous reports have paid much attention to the natural history of hepatitis C, as well as the many factors associated with disease progression including alcohol, male sex, older age at the time of infection, and longer duration of infection. However, little attention has been given to immunosuppression and its role in progression of HCV-related liver disease. After a mean follow-up of 18 years after transfusion-associated HCV infection, Seeff et al. found that there was no increase in overall mortality and only modest increases in morbidity and deaths related to liver disease in the infected group when compared with noninfected controls. After 20 years of follow-up, approximately 10% of the infected group showed evidence of cirrhosis. Conversely, numerous studies involving HIV and HCV coinfected patients and two studies regarding patients with primary hypogammaglobulinemia and HCV have clearly shown more rapidly progressive HCV-related liver disease among those with immunodeficiency. In addition, several studies have demonstrated increased HCV RNA levels among HIV positive patients when compared with their immunocompetent, HIV negative controls. In one study, which examined serial samples, HCV RNA levels increased as immune deficiency progressed over time.

We found that the HCV viral loads of leukemia survivors were markedly higher than a control group of HIV negative, immunocompetent, HCV positive patients of approximately the same age. This finding is more significant when one considers that the control group was infected for twice as long as the study group. These results suggest that the previously immunocompromised status of the leukemia survivors may have promoted more rapid viral replication or impaired host viral clearance. While none of our leukemia survivors have shown evidence of hepatic decompensation at a mean of 9 years after HCV infection, our results suggest that they may be at increased risk for more rapid disease progression. If so, a more aggressive approach regarding the use of antiviral therapy in the population of leukemia survivors with chronic HCV may be warranted.

ACKNOWLEDGMENT

We thank Mary Catherine Hess, RN, Drs James O. Ballard, Hamid Al-Mondhiry, W. Christopher Ehmann, Barbara Miller, L. Eamonn Neagley, Richard Dixon, David Prager, Michael Marrone, and Terrance Cescom for assistance with patient enrollment and data collection. Sara Neagley, RN, Elieshah Crago, RN, and Linda Landis for assistance with data collection; Allen Kunselman, MA, for help with biostatistics; and Linda Nelson for assistance with preparing the manuscript.

REFERENCES

48. Naito M, Hayashi N, Hagihara W, Hiramatsu N, Kasahara A, Fisamoto H, Kamada T: Serum hepatitis C virus RNA quantity and...
histological features of hepatitis C virus carriers with persistently normal ALT levels. Hepatology 19:871, 1994


53. Thiele DL: Commentary: Liver injury associated with hepatitis C infection: Is it the virus or is it the host? Hepatology 26:238, 1997

54. Seeff LB, the NHLBI Study Group: Mortality and morbidity of transfusion associated non-A, non-B (NANB) and type C hepatitis: An NHLBI multi-center study. Hepatology 20:204a, 1994 (abstr)
Chronic Hepatitis C Virus Infections in Leukemia Survivors: Prevalence, Viral Load, and Severity of Liver Disease

Ian M. Paul, Jeffrey Sanders, Francesca Ruggiero, Thomas Andrews, David Ungar and M. Elaine Eyster